tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
PremiumRatingsBuy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
5M ago
Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting
Premium
The Fly
Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting
5M ago
Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright
Premium
The Fly
Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright
5M ago
Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study
PremiumCompany AnnouncementsContext Therapeutics Advances in Cancer Treatment with CTIM-76 Study
5M ago
Context Therapeutics’ CT-95 Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Context Therapeutics’ CT-95 Study: A Potential Game-Changer in Cancer Treatment
5M ago
Context Therapeutics Amends Sales Agreement with Leerink
Premium
Company Announcements
Context Therapeutics Amends Sales Agreement with Leerink
5M ago
Context Therapeutics initiated with a Buy at Guggenheim
PremiumThe FlyContext Therapeutics initiated with a Buy at Guggenheim
6M ago
Context Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Context Therapeutics initiated with a Buy at Guggenheim
6M ago
Context Therapeutics management to meet with Maxim
Premium
The Fly
Context Therapeutics management to meet with Maxim
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100